Global Health Ventures Licenses Male Sexual Enhancement Drug From Globe Laboratories Inc.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 18, 2009) - Global Health Ventures Inc. (OTCBB: GHLV), a HealthCare Technology Merchant Bank, is pleased to announce the signing of a license agreement with Globe Laboratories Inc., a privately-held biotechnology company in Vancouver, Canada. Under the terms of the agreement, Globe Laboratories will license a new drug formulation for male sexual enhancement. The drug, which is in Phase I/II clinical trials, is expected to have a significant market once all trial studies and regulatory filings are completed. The entire financing for the project will be committed by Global Health Ventures, while Globe Laboratories will benefit from marketing of the product through royalties, milestones, and research contracts agreed to by the two companies.

About Global Health Ventures

Global Health Ventures is a ‘Healthcare Technology Merchant Bank’, and is in the business of acquisition and licensing of outstanding healthcare technologies for further development and re-licensing to major pharmaceutical companies. While venture capital and private equity firms tend to be investment-oriented, Global Health Ventures licenses, or buys the promising technologies from biotech companies with insufficient resources, or lack of appropriate management for further development. The Company develops the technologies to mid-stage Phase III clinical trials and then sells or licenses out to major pharmaceutical, biotechnology or speciality pharma worldwide for upfront fees, milestones, and royalties. Global Health Ventures has built a portfolio of products using its own capital from diverse broker dealers, as well as private and institutional investors.

Safe Harbour Statement

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing. Further the risk involves the ability of the Company to accelerate the development, and the ability to out-license the products as well as, the ability to raise sufficient funds for the development. Specifically, the risks and uncertainties that could affect the success of the Company includes risks associated with clinical developments, the ability of the Company to continue to raise capital to fund its operations and the capital requirements of the licensed-in products. Investors should also review the risk factors listed in the Company’s filings with the Securities and Exchange Commission.